New hope for kids with tough cancers: GAIA-102 trial launches
NCT ID NCT05608148
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and find the best dose for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kyushu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can AI read tumor slides to outsmart childhood cancer?
- Ultrasound, CT, and MRI put to the test for identifying childhood neck lumps
- Can a targeted pill stall advanced sarcomas?
- A simple blood test may reveal how ewing sarcoma responds to therapy